Please provide your email address to receive an email when new articles are posted on . The human monoclonal antibody denosumab more effectively increases bone mass in patients with low bone mineral ...

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

Over the last decade, goal-directed management of osteoporosis has been developed as a concept. In 2024, a working group of ...

Please provide your email address to receive an email when new articles are posted on . A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or ...

SAN FRANCISCO, CA—Treatment with Prolia (denosumab) or bisphosphonates was associated with a low incidence rate of potential osteonecrosis of the jaw among postmenopausal women with osteoporosis, ...

Treatment of osteoporosis with denosumab, compared with bisphosphonate therapy, may help prevent progression to type 2 diabetes (T2D) in those at high risk for it. In patients with osteoporosis who ...

Hypercalcemia of malignancy (HCM) is the most common metabolic complication seen in patients with cancer, and is associated with a high degree of morbidity and mortality. It affects an estimated 2%–30 ...

Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...

The human monoclonal antibody denosumab decreases bone resorption independently of previous treatment with bisphosphonates in patients with bone metastases. Bone metastases increase osteoclast ...

For female dialysis-dependent patients aged 65 years or older treated for osteoporosis, denosumab is associated with an increased incidence of severe or very severe hypocalcemia, according to a study ...